enGene is leader in nucleotide delivery to the intestine. The Company has developed a highly flexible nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. enGene’s platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic delivery of therapeutic proteins from the gut to treat diabetes, anemia, hemophilia and others. The Company is initially applying its technology to localize delivery of immune-modulating proteins to the intestinal mucosa for treating inflammatory bowel disease. For more information visit: www.engeneinc.com.